ArticleBMC medical genomics2025
First report of Leishmania RNA virus 2 and its high genetic diversity in cutaneous leishmaniasis cases from Ilam Province, Iran.
Article in BMC medical genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCutaneous Leishmaniasis (CL) is a vector-borne disease caused by a protozoan parasite and considered a public health challenge in many countries, including Iran. Recent research has focused on the role of Leishmania RNA virus (LRV) in the pathogenesis of cutaneous and mucosal forms of leishmaniasis. This study assessed the presence of LRV2 and its genotype diversity among isolates in Ilam province, western Iran, an old focus of Zoonotic CL. MATERIAL AND
methodThirty-two lesion specimens were collected from CL patients and subjected to PCR analysis using species-specific primers for Leishmania identification and detection of LRV2. The amplified products were sequenced, and phylogenetic analysis was performed.
resultAll samples were identified as L. major. The PCR showed that 4 of 32 (12.5%) clinical cultures were LRV2 positive. Phylogenetic analysis revealed high nucleotide sequence identity (96-99%) with LRV2 isolated from L. major strains from Iran, Turkey, and Uzbekistan. The four sequences analyzed revealed four distinct haplotypes, with high genetic variability among the isolates.
conclusionThis study provides the first identification and phylogenetic analysis of LRV2 in CL patients from western Iran and highlights the extensive genetic diversity among LRV2 isolates across different regions, which may have significant implications for disease pathogenesis, transmission patterns, and clinical manifestations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.